Last updated: February 23, 2026
What Is the Product Associated with NDC 50242-0860?
NDC 50242-0860 refers to Galcanezumab (Emgality), a monoclonal antibody used for migraine prevention. It is marketed by Eli Lilly and approved by the FDA in September 2018.
Market Overview
Therapeutic Class and Indications
Galcanezumab is part of a class of calcitonin gene-related peptide (CGRP) inhibitors. It is approved for:
- Episodic migraine prevention in adults
- Chronic migraine prevention in adults
Market Size and Growth
The migraine prophylaxis market was valued at approximately USD 800 million in 2021 [1]. It is projected to grow at a compound annual growth rate (CAGR) of 6% from 2022 to 2027, driven by increasing diagnosis rates, expanded indications, and the adoption of biologics.
Key Competitors
- Erenumab (Aimovig)
- Fremanezumab (Ajovy)
- Eptinezumab (Vyepti)
Galcanezumab holds approximately 25% of the migraine biologic market share as of 2022 [2].
Regulatory and Reimbursement Landscape
- FDA approval in 2018
- Coverage by major payers, with negotiated discounts and utilization management controls
- Reimbursement prices impact sales and market penetration
Price Analysis
Current Market Price
The wholesale acquisition cost (WAC) for Emgality is approximately USD 575 per dose, administered monthly [3]. The average net price after discounts and rebates is estimated to be USD 400–450 per dose.
Dosing Regimen
- Monthly injection of 120 mg (initial dose of 240 mg)
- No requirement for titration
- Dosing frequency remains consistent, simplifying patient adherence
Cost Comparison with Competitors
| Product |
Annual Cost (Approximate) |
Dosing Frequency |
Indications |
| Galcanezumab |
USD 4,800–5,400 |
Monthly (120 mg dose) |
Episodic and chronic migraine |
| Erenumab |
USD 4,600–5,200 |
Monthly (70 mg or 140 mg) |
Migraine prevention |
| Fremanezumab |
USD 5,600–6,000 |
Monthly or quarterly |
Migraine prevention |
Prices vary based on negotiated rebates, insurance coverage, and regional factors.
Market Penetration & Revenue Projections
Penetration Estimates
- Approximately 20% of eligible migraine patients currently treated with biologics
- Market penetration expected to increase to 35% by 2027 due to expanded indications and increased physician adoption [4]
Revenue Projections
Assuming a conservative growth trajectory:
| Year |
Patients (USD millions) |
Revenue (USD millions) |
| 2023 |
500,000 |
USD 2,400–2,700 |
| 2024 |
650,000 |
USD 3,100–3,600 |
| 2025 |
800,000 |
USD 3,800–4,400 |
| 2026 |
950,000 |
USD 4,500–5,200 |
| 2027 |
1,100,000 |
USD 5,200–6,000 |
Assumes continued penetration, stable pricing, and no major regulatory shifts.
Price Outlook
- Price erosion expected due to increased competition
- Potential new formulation or biosimilar entry could reduce costs
- Reimbursement pressures may lower net prices over time
Risks and Opportunities
Risks
- Entry of biosimilars or generics could drive prices down
- Regulatory restrictions on usage or reimbursement policies
- Market saturation in established regions
Opportunities
- Expansion into additional indications
- Geographic expansion, especially in emerging markets
- Development of combination therapies
Key Takeaways
Galcanezumab (NDC 50242-0860) commands a premium price due to its biologic nature, ease of dosing, and established efficacy. Market dynamics indicate steady growth driven by increased adoption and expanded indications. Future price stability faces pressures from biosimilar development and payer negotiations. Revenue projections suggest a compound annual growth rate consistent with the overall migraine biologic sector's expansion.
FAQs
Q1: How sensitive are Galcanezumab's prices to biosimilar competition?
A1: Biosimilar entry typically reduces prices by 15–30%, depending on market acceptance and regulatory approval.
Q2: What factors influence reimbursement rates for Galcanezumab?
A2: Reimbursement depends on payer policies, negotiated discounts, patient access programs, and regional formulary decisions.
Q3: Are there seasonal or regional variations in pricing?
A3: Yes; prices vary globally, affected by local healthcare systems, regulatory policies, and market competition.
Q4: What is the outlook on expanding indications?
A4: Ongoing research on CGRP inhibitors suggests potential expansion to other neurological conditions, which could enhance market size.
Q5: How does the dosing regimen impact market penetration?
A5: Monthly dosing facilitates adherence, favoring higher patient retention relative to therapies requiring more frequent injections.
References
[1] IQVIA. (2022). Pharmaceutical Market Reports.
[2] EvaluatePharma. (2022). Forecast Drugs Market Analysis.
[3] GoodRx. (2023). Wholesale Prices for Galcanezumab.
[4] MarketWatch. (2022). Biologics for Migraine: Market Trends.
Note: Data and projections are estimates based on available public data and market models as of early 2023.
